<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290407</url>
  </required_header>
  <id_info>
    <org_study_id>008.06</org_study_id>
    <secondary_id>BCC-HEM-06-001</secondary_id>
    <nct_id>NCT00290407</nct_id>
  </id_info>
  <brief_title>Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)</brief_title>
  <official_title>Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how well subjects respond to treatment with&#xD;
      Rituximab plus Beta-Glucan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. CLL is a&#xD;
      cancer of the B-lymphocytes, which make antibodies that help protect the body against harmful&#xD;
      foreign substances, such as bacteria and viruses. Similar to CLL, small lymphocytic lymphoma&#xD;
      (SLL) is a less-common cancer of the B-lymphocytes. In SLL, the abnormal lymphocytes mainly&#xD;
      affect the lymph nodes; in CLL, the abnormal lymphocytes mainly affect the blood and bone&#xD;
      marrow.&#xD;
&#xD;
      Current drug therapies for CLL/SLL are known to increase the severity of pre-existing low&#xD;
      blood cell counts, which in turn increase the risk of infections in patients. Research to&#xD;
      improve the safety and effectiveness of CLL/SLL therapy is currently ongoing. One such&#xD;
      therapy being investigated is Rituximab.&#xD;
&#xD;
      Rituximab is a type of drug known as a therapeutic antibody. Therapeutic antibodies are&#xD;
      laboratory-created substances that attach onto a protein on the surface of a cell. After&#xD;
      binding to the cell, the therapeutic antibody can block the growth of the tumor and/or&#xD;
      trigger the body's immune system to attack the target, and can also sensitize a cancer cell&#xD;
      to chemotherapy. Rituximab is approved by the Food and Drug Administration (FDA) for the&#xD;
      treatment of CLL/SLL.&#xD;
&#xD;
      Beta-Glucan (Imucell WGP) is an over-the-counter dietary supplement that enhances the body's&#xD;
      immune system. ImucellTM WGP is extracted from food-grade baker's yeast, which is permitted&#xD;
      for use in food by the FDA. Animal studies have shown that Imucell WGP helps trigger the&#xD;
      white blood cells to destroy cancer cells. Other animal studies combining Rituximab with&#xD;
      Imucell WGP have shown greater tumor regression and tumor-free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated due to lack of accrual&#xD;
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CT Scan to Measure Clinical Effect (Response)</measure>
    <time_frame>3 months after starting treatment, 6 months after starting treatment, and every 6 months (after completing treatment) until disease progression</time_frame>
    <description>Study terminated, results data not available</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Specimens Will be Collected to Measure Immunologic Effect</measure>
    <time_frame>at weeks 4, 8, 12, and at month 6</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2, IV (in the vein), once a week for 4 weeks</description>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-Glucan</intervention_name>
    <description>250 mg, orally (tablet), three times a day for 9 weeks</description>
    <other_name>Imucell WGP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  definitive diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic&#xD;
             Lymphoma (SLL)&#xD;
&#xD;
          -  Patients with CLL must have active, progressive, or symptomatic Rai stage II, III, or&#xD;
             IV disease. Patients with SLL must have active, progressive or symptomatic stages II,&#xD;
             III, IV disease by the Ann Arbor Staging system. Patients with stage I CLL are&#xD;
             eligible only if they have systemic symptoms requiring treatment.&#xD;
&#xD;
          -  Patients may be treatment naïve, refractory to primary therapy, or relapsed not more&#xD;
             than four times) and have measurable or assessable disease. Bone marrow involvement&#xD;
             alone will not be acceptable as measurable disease in case of lymphoma.&#xD;
&#xD;
          -  Prior therapies may include chemotherapy, radiation, autologous stem cell transplant,&#xD;
             or Rituximab.&#xD;
&#xD;
          -  Patients who have received therapy must be at least 4 weeks beyond prior standard&#xD;
             chemotherapy including corticosteroids, 3 months beyond radiation therapy, and have&#xD;
             recovered from significant toxicities from prior therapies&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  life expectancy of greater than 12 weeks&#xD;
&#xD;
          -  ECOG performance status 0, 1, or 2 (Karnofsky &gt; 50%)&#xD;
&#xD;
          -  adequate bone marrow function, as defined by: absolute neutrophil count &gt; 1000/µl;&#xD;
             platelets &gt; 20,000/µl&#xD;
&#xD;
          -  adequate liver function, as defined by: total bilirubin &lt; 2, albumin &gt; 2.5 g/dl, and&#xD;
             no ascites; AST(SGOT), ALT(SGPT) &amp; Alkaline Phosphatase &lt; 2.5 x upper limit of normal&#xD;
&#xD;
          -  adequate renal function, as defined by: creatinine &lt; 2.5 mg/dl or a creatinine&#xD;
             clearance &gt; 30 mL/min (measured or estimated by the Cockcroft-Gault formula) for&#xD;
             patients with creatinine levels above 2.5 mg/dl&#xD;
&#xD;
          -  must have recovered from acute toxicities resulting from prior therapy to less than&#xD;
             grade 1. Alopecia may not be resolved.&#xD;
&#xD;
          -  ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to study entry or who have not recovered from&#xD;
             adverse events due to agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  severe autoimmune hemolytic anemia; CNS involvement (either parenchymal or meningeal);&#xD;
             severe lymphoma-related symptoms requiring a rapid response to therapy (eg,&#xD;
             respiratory compromise due to large effusions or airway obstruction, bowel&#xD;
             obstruction, ureteral obstruction, and chylous ascites)&#xD;
&#xD;
          -  patients receiving any other investigational agent(s)&#xD;
&#xD;
          -  active second malignancy in the last 5 years, except for non-melanoma skin cancer or&#xD;
             carcinoma-in-situ&#xD;
&#xD;
          -  history of hypersensitivity reactions attributed to Beta-Glucan&#xD;
&#xD;
          -  history of connective tissue or autoimmune disease&#xD;
&#xD;
          -  patients receiving corticosteroids for any reason, except as a part of treatment for&#xD;
             autoimmune hemolytic anemia or immune thrombocytopenia&#xD;
&#xD;
          -  uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger H Herzig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center/University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://browncancercenter.org</url>
    <description>James Graham Brown Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>May 3, 2013</results_first_submitted>
  <results_first_submitted_qc>May 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2013</results_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>small lymphocytic lymphoma</keyword>
  <keyword>rituximab</keyword>
  <keyword>beta-glucan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RITUXIMAB PLUS ORAL Β-GLUCAN</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RITUXIMAB PLUS ORAL Β-GLUCAN</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Over 18 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CT Scan to Measure Clinical Effect (Response)</title>
        <description>Study terminated, results data not available</description>
        <time_frame>3 months after starting treatment, 6 months after starting treatment, and every 6 months (after completing treatment) until disease progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RITUXIMAB PLUS ORAL Β-GLUCAN</title>
          </group>
        </group_list>
        <measure>
          <title>CT Scan to Measure Clinical Effect (Response)</title>
          <description>Study terminated, results data not available</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Specimens Will be Collected to Measure Immunologic Effect</title>
        <time_frame>at weeks 4, 8, 12, and at month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RITUXIMAB PLUS ORAL Β-GLUCAN</title>
          </group>
        </group_list>
        <measure>
          <title>Blood Specimens Will be Collected to Measure Immunologic Effect</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RITUXIMAB PLUS ORAL Β-GLUCAN</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated, results data not available</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Roger H Herzig, MD</name_or_title>
      <organization>James Graham Brown Cancer Center</organization>
      <phone>502/396-3119</phone>
      <email>rhherz01@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

